Drug Approval | October 09, 2023
Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
The development comes as stroke remains one of the world’s biggest health threats
Access to genomic testing, not therapy cost, is the biggest challenge
Subscribe To Our Newsletter & Stay Updated
